克癌临治疗移植性肝癌(H_(22))的实验研究

Experimental Study on Keailin Decoction in the Treatment of Transplanted Hepatocarcinoma22(H 22 )

本文报告了克癌临水煎液对小鼠移植性肝癌（Ｈ２２）的治疗作用。以该药２２７ｇ／ｋｇ·Ｗ灌服荷实体型肝癌（Ｈ２２）小鼠，能显著抑制其肿瘤生长，肿瘤抑制率达５１３％；并能明显抑制荷瘤机体肿瘤坏死因子（ＴＮＦ）水平的异常增高，使其维持在一定水平而发挥抗肿瘤、调节机体免疫力等作用。经流式细胞术检测，表明该药还可阻滞肿瘤细胞从细胞周期Ｇ１期向Ｓ期的转变过程，阻断ＤＮＡ合成和复制，并进一步诱发其发生较高水平的细胞凋亡。

The results of Keailin Decoction(KALD)in the treatment of trunsplanted hepatocarcinoma(H 22 )were reported.The resulrs indicated that KALD(22 7g/kg)continuously given orally to mice having H 22 could obviously result in the inhibition of tumor growth,and the rate of inhibition was 51 3%.KALD also could significantly inhibit the abnormal elevation of TNF of tumor bearing mice,and TNF would maintain at a certain level to take the effect in antitumor and regulation of immunity.In flow cytometry(FCM)analysis,KALD could hinder the transformation(from G l phase to S phase)of tumor cells cycle,and inhibit the synthesis and duplication of DNA.Furthermore,KALD also could induce apoptosis of tumor cells on high level.All these results might be the important mechanism of KALD being capable to treat experimental H 22 .